ERBB2 and neoplasm: Patients with HR+/HER2− and HER2+ MBC received longer durations of systemic therapy than patients with TNBC, likely due to the better tolerability of ET and HER2-targeting agents than cytotoxic chemotherapy and different tumor biology (Figure 2).